NCT Dresden starts Phase 2 trial with mRNA vaccine against pancreatic cancer
The National Center for Tumor Diseases (NCT/UCC) Dresden is offering patients with pancreatic cancer an innovative treatment with the mRNA-based cancer vaccine Autogene Cevumeran as part of the international phase 2 trial IMCODE003 (NCT05968326). The vaccine developed by BioNTech and Genentech targets tumor-specific neoantigens to activate the immune system against remaining tumor cells after surgery.
Pancreatic cancer is considered one of the deadliest types of cancer, with a high relapse rate and a five-year survival rate of only around 25 to 33 percent despite chemotherapy. A phase 1 study showed a strong T-cell immune response and a reduced risk of relapse in half of the patients treated.
The current study compares the efficacy and safety of autogene cevumeran in combination with the PD-L1 inhibitor atezolizumab and the chemotherapy mFOLFIRINOX against chemotherapy alone in patients without metastases who have not yet received chemotherapy or radiotherapy. As the only center in Saxony involved, the NCT/UCC Dresden emphasizes the importance of interdisciplinary cooperation, as participation in the study must take place directly after surgery. Interested parties can contact the NCT/UCC study secretariat.
Contact:
NCT/UCC study secretariat: oncostudy@ukdd.de
Original publication:
IMCODE003-Studie (NCT05968326): A study of the efficacy and safety of adjuvant autogeneous Cevumeran plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX alone in participants with resected PDAC (NCT05968326)
The articles in the news section are produced by X-Press journalist office
Gender note. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple references and gendered designations are avoided in favor of better readability.
Most read
Measles: Vaccination gaps in small children alarm health insurance companies A current data analysis by the posted on 18. July 2025- Virtual shock room at Ulm University digitally enhances medical studies The Faculty of Medicine at Ulm University is introducing an innovative training method for medical s...
- Hamburg becomes a pioneer: PROVIREX enables local CAR-T cell production CAR T-cell therapy has been revolutionizing the treatment of certain blood cancers in Germany since...
